Press Release Details

Belgium Mandates Universal Pathogen Inactivation for Platelets

July, 16 2009

CONCORD, Calif. -- Cerus Corporation (NASDAQ:CERS) announced today that Belgium has issued a Royal Decree mandating universal use of pathogen inactivation for platelets. Under the terms of the decree, Belgian blood centers are required to fully implement use of pathogen inactivation no later than August of 2010. A Ministerial Decree was issued on the same day, establishing specific reimbursement for pathogen inactivated platelet products, effective immediately. The government's decision is consistent with a 2008 recommendation from the Belgian High Council of Health advocating treatment of platelets to reduce the routine risk of transfusion-transmitted infections, as well as safeguarding the platelet supply in the event of pandemic influenza.

"We commend the Belgian government on its leadership within the field of transfusion safety, which now includes becoming the first country to require pathogen inactivation of both platelets and plasma for transfusion," said Dr. Laurence Corash, senior vice president and chief medical officer of Cerus. "We are proud of the contribution that the INTERCEPT Blood System is already making toward protecting patients from transfusion-transmitted threats."

The INTERCEPT Blood System has been used in Belgium since 2003 for treatment of platelets, and since 2007 for treatment of plasma. It is currently used by blood centers in Yvoir, Brugge, Charleroi, Brabant-Hainaut, Liege, and Namur, and also by the Belgian Army blood service, representing approximately 40% of the platelets collected in Belgium.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is currently in clinical development. See http://www.cerus.com for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600